Former Vermont governor and erstwhile Democratic presidential candidate Howard Dean is publicly urging President Joe Biden to oppose a South Africa- and India-led effort to temporarily lift coronavirus vaccine patents, a move that would help facilitate broad-based generic production of vaccines for developing nations.
In an op-ed for Barron's last month, Dean—who currently works in the lobbying division of the global law firm Dentons—claimed that India's sponsorship of the proposed intellectual property waiver is nothing more than a "thinly veiled attempt to boost its drug industry" and argued that "President Biden would be wise to reject it."
"Suspending IP protections won't speed up Covid-19 vaccine production," Dean declared. "Every drug manufacturing facility on the planet that's capable of churning out Covid-19 shots is already doing so."
But as The Intercept's Lee Fang noted Thursday, "Dean's claim that global vaccine manufacturing is already at capacity is patently false."
"Foreign firms have lined up to offer pharmaceutical plants to produce vaccines but have been forced to enter into lengthy negotiations under terms set by the intellectual property owners," Fang wrote. "The waiver, however, would allow generic drug producers to begin copying the vaccine without delay."
The Associated Press reported last month that on three continents, it found factories "whose owners say they could start producing hundreds of millions of Covid-19 vaccines on short notice if only they had the blueprints and technical know-how."
Previously a supporter of single-payer healthcare, Dean was considered a "progressive outsider" when he contended for the Democratic presidential nomination in 2004. But Dean has dramatically changed his tune since joining Dentons, a global law firm that has done work on behalf of corporations in a variety of industries, including healthcare.
SCROLL TO CONTINUE WITH CONTENT
Never Miss a Beat.
Get our best delivered to your inbox.
"Dentons touts its work on drug intellectual property issues, noting on its website that it has represented Pfizer and other firms in the recent past," Fang pointed out. "[Dean's] official role is as a senior advisor to its government affairs practice focused on corporate healthcare clients, though as The Intercept has previously reported, he engages in almost every lobbying activity imaginable."
First introduced at the World Trade Organization (WTO) in October, South Africa and India's patent waiver proposal has since garnered the support of more than a 100 countries, hundreds of progressive advocacy organizations, U.S. members of Congress, Nobel Prize-winning economists, and the head of the World Health Organization. Predictably, the pharmaceutical industry has lobbied against the waiver.
Because the WTO operates on consensus, a small number of rich nations—including the U.S., the U.K., and members of the European Union—have been able to block the proposal, leaving large pharmaceutical companies in control of vaccine production and denying the recipes to low-income nations.
At the current rate of vaccine production and distribution, experts fear that most poor nations could take until 2024 to achieve mass inoculation against Covid-19, a delay that could allow vaccine-resistant variants to emerge and spread widely.
"The waiver is supported by over 100 countries and being opposed by only a handful of rich countries," Rep. Jan Schakowsky (D-Ill.) wrote in a Medium post last month. "The world needs as much vaccine manufacturing capacity as it can get. Time is of the essence."